| Title: | Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia |
| Other Titles: | Clinical impact of pre-transplant use of multiple tyrosine kinase inhibitors on the outcome of allo-HSCT for CML |
| Use of multiple TKIs before allo-HSCT for CML |
| Authors: | Kondo, Takeshi Browse this author →KAKEN DB |
| Nagamura-Inoue, Tokiko Browse this author |
| Tojo, Arinobu Browse this author |
| Nagamura, Fumitaka Browse this author |
| Uchida, Naoyuki Browse this author |
| Nakamae, Hirohisa Browse this author |
| Fukuda, Takahiro Browse this author |
| Mori, Takehiko Browse this author |
| Yano, Shingo Browse this author |
| Kurokawa, Mineo Browse this author |
| Ueno, Hironori Browse this author |
| Kanamori, Heiwa Browse this author |
| Hashimoto, Hisako Browse this author |
| Onizuka, Makoto Browse this author |
| Takanashi, Minoko Browse this author |
| Ichinohe, Tatsuo Browse this author |
| Atsuta, Yoshiko Browse this author |
| Ohashi, Kazuteru Browse this author |
| Issue Date: | Sep-2017 |
| Publisher: | John Wiley & Sons |
| Journal Title: | American journal of hematology |
| Volume: | 92 |
| Issue: | 9 |
| Start Page: | 902 |
| End Page: | 908 |
| Publisher DOI: | 10.1002/ajh.24793 |
| PMID: | 28543934 |
| Abstract: | Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with chronic myelogenous leukemia in the chronic phase (CML-CP), and outcomes of TKI treatment for patients with CML-CP have been excellent. Since multiple TKIs are currently available, second-line or third-line TKI therapy is considered for patients who are intolerant of or resistant to the previous TKI treatment. Therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered only for patients with disease progression or for patients after treatment failure with multiple TKIs. To reflect the current clinical situation of patients with CML-CP, we tried to clarify whether prior TKI treatment affects the outcome of allo-HSCT. Data from 237 patients for whom the number of pretransplant TKIs varied from one to three were used for analysis. Before allo-HSCT, 153 patients were treated with one TKI, 49 patients were treated with two TKIs and 35 patients were treated with three TKIs. In addition to conventional risk factors, i.e., disease status at transplantation and patient's age, the use of three TKIs before transplantation was identified as a significant adverse factor for prognosis. Nonrelapse mortality rate was higher in patients treated with three TKIs than in patients treated with one or two TKIs. Our results suggest that allo-HSCT could be considered for young patients with CML-CP who manifest resistance to second-line TKI therapy and who have an appropriate donor. |
| Rights: | This is the peer reviewed version of the following article: Kondo T, Nagamura-Inoue T, Tojo A, et al. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Am J Hematol. 2017;92:902–908., which has been published in final form at https://doi.org/10.1002/ajh.24793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/71411 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
